Premium
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real‐life study
Author(s) -
Pellicelli Adriano M.,
Pace Palitti Valeria,
Vignally Pascal,
CeccheriniSilberstein Francesca,
Siciliano Massimo,
Giannelli Valerio,
Moretti Alessandra,
Tarquini Pierluigi,
Scifo Gaetano,
Messina Vincenzo,
Ascione Antonio,
Izzi Antonio,
Marignani Massimo,
D'Ambrosio Cecilia,
Fondacaro Lucia,
Ettorre Giuseppe M.,
Ialongo Pasquale,
Sacco Rodolfo,
Perno Carlo F.,
Barbarini Giorgio
Publication year - 2017
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13288
Subject(s) - sofosbuvir , simeprevir , ribavirin , medicine , genotype , gastroenterology , virology , pharmacology , hepatitis c virus , biology , virus , biochemistry , gene
Background & Aims The proportion of HCV ‐infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real‐world efficacy and safety of the combination of sofosbuvir ( SOF ) and simeprevir ( SMV ) plus a flat dose of 800 mg/d ribavirin ( RBV ) in elderly patients with cirrhosis compared to younger patients. Methods Retrospective observational multicentre real‐life investigation study of SOF / SMV / RBV for a duration of 12 weeks in HCV genotype 1‐infected patients with cirrhosis. Results Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were ≥65 years of age. Sustained virological response at 12 weeks ( SVR 12) was achieved by 94.2% (129/137) of those aged <65 years and 97.7% (130/133) of those ≥65 years. Diabetes was the most common comorbidity in patients ≥65 years compared to younger patients (26.3% vs 12.4% P <.003). The most common adverse event ( AE ) in elderly patients was a grade 2 anaemia (35.3% vs 19.9% P <.004). Conclusions Sofosbuvir/simeprevir plus a daily flat dose of RBV 800 mg for 12 weeks was highly effective and safe in genotype 1 elderly patients with compensated cirrhosis.